ZOETIS (ZTS) DIvidends Date & History

Key Takeaways

• Zoetis offers a current dividend yield of 1.86%, with an annual payout of $2.12 per share.
• The company pays quarterly dividends, with the most recent ex-dividend date on April 20, 2026, and payment on June 2, 2026, at $0.53 per share.
• Zoetis has raised its dividend for 14 consecutive years, with a 5-year average annual growth rate of over 20%.
• Payout ratio stands at approximately 33-35%, indicating strong sustainability supported by robust free cash flow.
• Low payout and consistent earnings growth make ZTS appealing for dividend growth investors.

Dividend Overview

Zoetis Inc. (ZTS), the global leader in animal health, maintains a modest dividend profile suited for growth-oriented income investors. The company currently yields 1.86%, derived from its quarterly dividend of $0.53 per share, equating to an annual $2.12. Payments occur quarterly, with the latest declaration reflecting a 6% increase from prior levels. This positions ZTS as a dividend growth stock rather than a high-yield play, emphasizing reinvestment in innovation within veterinary pharmaceuticals and services. The policy balances shareholder returns with funding for research and expansion in companion and livestock segments, fostering long-term value.

Dividend History and Growth

Since its 2013 spin-off from Pfizer, Zoetis has built a commendable dividend track record, achieving 14 consecutive years of increases as of 2026. Annual payouts have grown substantially: from 65.6 cents in 2019 to $2.12 today, reflecting compound annual growth exceeding 15% over the past decade. Recent hikes include a jump from $0.50 to $0.53 per quarter in late 2025, underscoring commitment amid operational strength. No cuts have occurred, with payments consistently quarterly, signaling a strategy prioritizing reliable, escalating returns for investors.

Dividend Sustainability and Payout Ratio

Zoetis' dividend appears highly sustainable, with a payout ratio of 33-35% of earnings, leaving ample room for growth and reinvestment. Earnings per share comfortably cover the $2.12 annual dividend, while free cash flow (FCF) generation remains robust at over $2 billion annually, exceeding dividend obligations multiple times. Moderate debt levels and strong cash flows from core animal health operations further bolster stability. Projections indicate continued FCF growth, supporting ongoing raises without strain.

Dividend Compared to Industry Peers

In the animal health subsector of healthcare, Zoetis' 1.86% yield is modest yet competitive, particularly given its superior growth profile. Direct peers like IDEXX Laboratories (IDXX) pay no dividend, focusing on reinvestment, while broader pharma firms such as Merck (MRK) offer higher yields around 3% but slower growth. Elanco Animal Health (ELAN) trails with inconsistent payouts. ZTS's combination of reliability and double-digit historical increases stands out, appealing to those seeking quality over top yield in a defensive industry.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Is This Stock Attractive for Dividend Investors?

Zoetis suits dividend growth investors prioritizing consistent raises over immediate high income, given its 14-year streak and 20%+ average 5-year growth rate alongside a safe 33% payout ratio. Long-term holders in defensive sectors may appreciate the stability from recurring animal health demand, less cyclical than human pharma. Conservative investors could value the low yield's backing by strong FCF and earnings coverage, minimizing cut risks. However, those chasing yields above 4% might look elsewhere, as ZTS trades at a premium valuation reflecting growth prospects. Income seekers balancing total returns with moderate payouts will find it analytically sound, though sector headwinds like regulatory pressures warrant monitoring.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations